Michael Levy
#176,580
Most Influential Person Now
American neurologist
Michael Levy's AcademicInfluence.com Rankings
Michael Levymedical Degrees
Medical
#3649
World Rank
#4140
Historical Rank
Neurology
#329
World Rank
#422
Historical Rank
Michael Levyphilosophy Degrees
Philosophy
#10836
World Rank
#14873
Historical Rank
Logic
#7684
World Rank
#9518
Historical Rank
Download Badge
Medical Philosophy
Michael Levy's Degrees
- Doctorate Medicine Harvard University
- PhD Neuroscience Stanford University
Why Is Michael Levy Influential?
(Suggest an Edit or Addition)Michael Levy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International consensus diagnostic criteria for neuromyelitis optica spectrum disorders (2015) (2486)
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing (2018) (483)
- The varicella zoster virus vasculopathies (2008) (323)
- Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. (2012) (313)
- Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2019) (269)
- Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. (2012) (254)
- Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. (2014) (253)
- Treatment of Neuromyelitis Optica: Review and Recommendations. (2012) (220)
- Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography (2015) (204)
- Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange (2016) (176)
- Superficial siderosis: a case report and review of the literature (2007) (158)
- The COVID-19 pandemic and the use of MS disease-modifying therapies (2020) (157)
- Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients (2014) (156)
- Neuromyelitis optica pathogenesis and aquaporin 4 (2008) (147)
- MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. (2018) (145)
- Neuromyelitis optica (2020) (130)
- Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic (2015) (116)
- Update on biomarkers in neuromyelitis optica (2015) (104)
- Racial differences in neuromyelitis optica spectrum disorder (2018) (103)
- In vivo identification of morphologic retinal abnormalities in neuromyelitis optica (2013) (97)
- Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging (2016) (97)
- Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. (2020) (87)
- Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia (2018) (82)
- Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
- Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder (2016) (79)
- Area postrema syndrome (2018) (76)
- Neuromyelitis optica spectrum disorders in children and adolescents (2016) (72)
- Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis (2015) (67)
- Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System (2012) (64)
- MRI differences between MOG antibody disease and AQP4 NMOSD (2020) (62)
- Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. (2015) (62)
- Immunopathogenesis of neuromyelitis optica. (2014) (60)
- Mortality in neuromyelitis optica is strongly associated with African ancestry (2018) (59)
- Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy (2018) (59)
- A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis (2012) (57)
- Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning (2020) (56)
- Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes (2015) (52)
- Pilot Safety Trial of Deferiprone in 10 Subjects With Superficial Siderosis (2012) (51)
- Safe and effective intravenous thrombolysis for acute ischemic stroke caused by left atrial myxoma. (2009) (51)
- Use of MR cell tracking to evaluate targeting of glial precursor cells to inflammatory tissue by exploiting the very late antigen-4 docking receptor. (2012) (51)
- Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4 (2016) (49)
- High risk of postpartum relapses in neuromyelitis optica spectrum disorder (2017) (49)
- MOG antibody–associated encephalomyelitis/encephalitis (2019) (48)
- Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica (2014) (48)
- Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. (2019) (47)
- Treatment of MOG antibody associated disorders: results of an international survey (2020) (47)
- Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic (2011) (47)
- Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica (2015) (43)
- Rethinking high-risk groups in COVID-19 (2020) (42)
- Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. (2017) (41)
- Investigational drugs in development to prevent neuromyelitis optica relapses (2018) (41)
- Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders (2018) (40)
- Challenges and opportunities in designing clinical trials for neuromyelitis optica (2015) (38)
- Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. (2019) (37)
- Predictors of recurrence following an initial episode of transverse myelitis (2014) (37)
- Bevacizumab is safe in acute relapses of neuromyelitis optica (2015) (37)
- Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. (2019) (36)
- Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders (2021) (35)
- Regenerative cellular therapies for neurologic diseases (2016) (34)
- n-Dodecyl-β-d-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity (2011) (33)
- Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. (2018) (33)
- Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica (2018) (32)
- A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder (2019) (30)
- Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases (2021) (30)
- Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. (2017) (30)
- Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder (2016) (30)
- Two‐year observational study of deferiprone in superficial siderosis (2017) (30)
- Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. (2019) (28)
- Deferiprone Reduces Hemosiderin Deposits in the Brain of a Patient with Superficial Siderosis (2010) (28)
- Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study (2017) (28)
- Restoring immune tolerance in neuromyelitis optica (2016) (27)
- Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity (2010) (26)
- Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: A multicenter, retrospective study (2018) (25)
- Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD (2021) (25)
- Revised Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders (S63.001) (2014) (24)
- Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. (2019) (24)
- Low serum vitamin D levels and recurrent inflammatory spinal cord disease. (2012) (24)
- Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis (2013) (22)
- Long COVID or post COVID-19 syndrome (2021) (21)
- Restoring immune tolerance in neuromyelitis optica (2016) (21)
- Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. (2019) (20)
- What do we know about brain contrast enhancement patterns in neuromyelitis optica? (2016) (20)
- Dry beriberi mimicking Guillain–Barre syndrome as the first presenting sign of thiamine deficiency (2012) (19)
- Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. (2022) (19)
- Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy (2020) (18)
- Spinal Movement Disorders in Neuromyelitis Optica: An Under‐recognized Phenomenon (2016) (17)
- Update on a Patient with Superficial Siderosis on Deferiprone (2012) (17)
- Scrambler therapy improves pain in neuromyelitis optica (2020) (17)
- Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results (2017) (16)
- Diagnosing CNS Vasculitis: The Case Against Empiric Treatment (2012) (16)
- Review of Animal Models of Neuromyelitis Optica. (2012) (16)
- Noninvasive Monitoring of Immunosuppressive Drug Efficacy to Prevent Rejection of Intracerebral Glial Precursor Allografts (2012) (15)
- Treatment of MOG-IgG-associated demyelination with Rituximab: a multinational study of 98 patients (2018) (15)
- Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD (2019) (15)
- Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder (2016) (15)
- Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. (2020) (15)
- Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta (2018) (14)
- Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. (2019) (14)
- Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice (2021) (14)
- Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (2021) (13)
- Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension (2021) (13)
- Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD (2020) (12)
- Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts (2018) (12)
- Update on neuromyelitis optica spectrum disorder. (2020) (11)
- Rituximab during pregnancy in neuromyelitis optica: A case report (2019) (11)
- Temozolomide and Radiation for Aggressive Pediatric Central Nervous System Malignancies (2005) (11)
- Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. (2021) (11)
- The Preoperative Neurological Evaluation (2013) (11)
- Reversible chest tube horner syndrome. (2008) (10)
- Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. (2019) (10)
- Auditory Profile in Superficial Siderosis of the Central Nervous System: A Prospective Study (2013) (10)
- Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis (2019) (10)
- Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. (2019) (9)
- COVID-19 vaccines and multiple sclerosis disease-modifying therapies (2021) (9)
- Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder (2021) (9)
- Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis (2020) (8)
- Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab (2015) (8)
- Evidence for classic complement activity in neuromyelitis optica (2014) (7)
- Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders (2018) (7)
- Is EBV the cause of multiple sclerosis? (2022) (7)
- Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. (2020) (7)
- Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. (2019) (7)
- Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder (2021) (6)
- Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. (2021) (6)
- Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis. (2019) (6)
- Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders (2017) (6)
- MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology (2019) (6)
- Risk of Hematoma From Aspirin or Clopidogrel Owing to Lumbar Puncture. (2019) (6)
- Vaccines and disease-modifying treatments. (2018) (6)
- Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review (2022) (5)
- Ethnic Differences in Clinical Manifestation of Neuromyelitis Optica Spectrum Disorder (2018) (5)
- The ethics of placebo controlled clinical trials in NMO - A balance of risks. (2015) (5)
- Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life (2021) (5)
- Long-term safety and effectiveness of eculizumab in neuromyelitis optica spectrum disorder (2019) (5)
- Cognitive functions in Egyptian neuromyelitis optica spectrum disorder. (2019) (5)
- Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective. (2021) (5)
- Does aquaporin-4-seronegative neuromyelitis optica exist? (2014) (5)
- B cell therapy and the use of RNA-based COVID-19 vaccines (2021) (5)
- Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders (2021) (5)
- Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin. (2021) (5)
- Is the incidence of multiple sclerosis really increasing? (2020) (4)
- Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study (2019) (4)
- Finding NMO (2008) (4)
- Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort (2022) (4)
- Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease (2022) (4)
- Expanding the spectrum of MOG antibody disease (2020) (4)
- Implications of Low-Titer MOG Antibodies. (2022) (4)
- A Novel GFAP Mutation in Late-Onset Alexander Disease Showing Diffusion Restriction (2017) (3)
- Update on neuromyelitis optica spectrum disorder. (2020) (3)
- Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (2020) (3)
- Familial monophasic acute transverse myelitis due to the pathogenic variant in VPS37A (2018) (3)
- Ten years of iron chelation in a patient with superficial siderosis (2019) (3)
- Paroxysmal symptoms in neuromyelitis optica spectrum disorder: Results from an online patient survey. (2020) (3)
- New Acute Severity Scale for Neuromyelitis Optica Relapses (P5.249) (2015) (3)
- Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis (2017) (3)
- Neuromyelitis optica unmasked by a spinal dural arteriovenous fistula (2016) (3)
- Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study (2020) (3)
- Multiple Sclerosis and Vitamin D - Caviar or a Dog's Dinner? (2019) (3)
- Air pollution and multiple sclerosis risk. (2021) (3)
- Multiple sclerosis is one disease. (2022) (3)
- Big pharma and social responsibility. (2020) (3)
- Is multiple sclerosis overdiagnosed? (2021) (2)
- Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study (2019) (2)
- Refining the Nosology of Antigen-Specific Diseases Within the Spectrum of Neuromyelitis Optica. (2018) (2)
- What is the true clinicopathologic spectrum of neuromyelitis optica?-Reply. (2013) (2)
- Effect of CXCR2 Inhibition on Behavioral Outcomes and Pathology in Rat Model of Neuromyelitis Optica (2018) (2)
- Brain MRI Differences Between MOG Antibody Disease and AQP4 NMOSD (2020) (2)
- A Real-World Analysis of Relapses and Costs of Neuromyelitis Optica Spectrum Disorders Using a United States Administrative Claims Database (P6.161) (2016) (2)
- Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. (2021) (2)
- Silent symptoms of multiple sclerosis. (2019) (2)
- Minimally-invasive Technique for Injection into Rat Optic Nerve. (2015) (2)
- Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease (2022) (2)
- Multiple sclerosis and migration revisited. (2019) (2)
- Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression (2019) (2)
- Optic Neuritis–Independent Retinal Atrophy in Neuromyelitis Optica Spectrum Disorder (2021) (1)
- EBV as the "gluten of MS" hypothesis provides a rationale for trialing antiviral therapies. (2022) (1)
- Efficacy and Safety of Eculizumab in Asian Patients WithAquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder: Subgroup Analysis From the Phase 3 PREVENT Study (2020) (1)
- ONSET OF MULTIPLE SCLEROSIS IS PREVENTABLE - TIME TO ACT NOW! (2022) (1)
- Facilitating Early-In-Day Discharge for Multiple Sclerosis Patients Treated With Intravenous Methylprednisolone (2015) (1)
- Diagnosis of multiple sclerosis: Progress or confusion? (2022) (1)
- Impact of eculizumab on hospitalization rates and relapse treatment in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (2019) (1)
- Is multiple sclerosis a risk factor for infections? (2020) (1)
- Should our treatment target in MS include the intrathecal plasma cell response? (2019) (1)
- Pain, Fatigue and Depression in Patients with Neuromyelitis Optica Spectrum Disorder in Europe and USA (P6.155) (2016) (1)
- Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies. (2021) (1)
- Defining Area Postrema (AP) Attacks in Autoimmune AQP4 Channelopathies/Neuromyelitis Optica Spectrum Disorders (NMOSD) (P6.386) (2017) (1)
- Clinical Reasoning: A patient with a history of encephalomyelitis and recurrent optic neuritis (2017) (1)
- Editorial: Epidemiology of Atypical Demyelinating Diseases (2021) (1)
- Differentiating NMO and MS-Associated Optic Neuritis by MRI (S63.002) (2014) (1)
- Is there a link between neuropathic pain and constipation in NMOSD and MOGAD? Results from an online patient survey and possible clinical implications. (2022) (1)
- Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788) (2020) (1)
- Long-term Safety and Efficacy of Eculizumab in Asian Patients With Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder (2020) (1)
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2023) (1)
- High Risk of Initial Symptom Onset Post-Partum in Neuromyelitis Optica (S60.001) (2013) (1)
- A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder” (2022) (1)
- Ageing and multiple sclerosis. (2020) (1)
- A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica. (2022) (1)
- Treatment outcomes of first-ever episode of severe optic neuritis. (2022) (1)
- Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from the Phase 3 PREVENT Study (1788) (2020) (1)
- Subgroup analyses from the Phase 3 PREVENT study in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (2019) (1)
- Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. (2021) (1)
- Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494) (2020) (1)
- Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder (1494) (2020) (1)
- Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658) (2020) (0)
- Long Term Disability in Neuromyelitis Optica Spectrum Disorder Is Associated with Number of Relapses, MRI Lesion Length and Race (P4.150) (2016) (0)
- Early Predictors of Relapses versus Pseudorelapses in Neuromyelitis Optica Spectrum Disorder (P6.156) (2016) (0)
- Dare we mention the C-word? (2020) (0)
- High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. (2022) (0)
- How not to get your article published. (2021) (0)
- Editors' Welcome. (2018) (0)
- The Spectrum of Myelopathies in Children: Beyond Idiopathic Transverse Myelitis (P2.306) (2018) (0)
- The future of microbiome research in neuroinflammatory disorders. (2020) (0)
- Impact of Eculizumab on Health Outcomes in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Findings from the PREVENT Study (2020) (0)
- Grassroot efforts towards diversity in MS care and research: Win-win for patients and science. (2019) (0)
- Are the high-costs of MS disease-modifying therapies justified? (2018) (0)
- Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica (2015) (0)
- WITHDRAWN: A narrative to explain worsening secondary progressive multiple sclerosis (2019) (0)
- B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20 (2021) (0)
- Diagnosing and caring for MS in Haiti. (2018) (0)
- Three suggestions to decrease the financial burden of MS treatments. (2019) (0)
- What are T-cells telling us about how EBV causes MS? (2022) (0)
- Screen for Novel Anti-Astrocytic Antibodies in Patients with Autoimmune and Paraneoplastic Encephalitis (P4.061) (2015) (0)
- Multiple types of relapses in MOG antibody disease. (2023) (0)
- neuromyelitis optica from multiple sclerosis (2015) (0)
- Acute flaccid myelitis in the 21st century: reminiscence of poliomyelitis or a new emergent disease. (2019) (0)
- episode of transverse myelitis (2014) (0)
- Inequality in accessing healthcare for people with MS. (2023) (0)
- MRI Lesion Length in Acute Optic Neuritis Correlates with Degree of Inner Retinal Thinning in Multiple Sclerosis (P2.120) (2016) (0)
- Why should Neurologists get involved in family planning? (2020) (0)
- One size doesn't fit all. (2019) (0)
- Editors' Welcome. (2018) (0)
- Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: the Phase 3 PREVENT Study (2020) (0)
- Vaccine hesitancy in people with multiple sclerosis (2022) (0)
- Linking X to MS: Immunity and demyelination on the X-chromosome in MS. (2022) (0)
- Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey. (2023) (0)
- Temozolomide (TMZ) and radiation (XRT) for aggressive pediatric CNS malignancies. (2004) (0)
- The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis (2023) (0)
- "Rocking the boat" with a new drug for neuromyelitis optica spectrum disorder. (2020) (0)
- Editors' Welcome. (2018) (0)
- Tissue Immunofluorescence Confirmation of CNS Autoantibodies Identified by Immunoblot or Cell-Based Assay (2020) (0)
- The biological rabbit hole: Only for the blind. (2022) (0)
- Recurrent Dysarthria and Ataxia in a Young Girl. (2018) (0)
- Cancer risk and mortality in multiple sclerosis: The need for vigilance. (2023) (0)
- Is cognitive impairment in multiple sclerosis reversible? (2018) (0)
- "Is this new medicine going to help me walk again?" (2020) (0)
- Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review (2022) (0)
- Are we ready for CD19-targeted CAR T-cell therapies in MS? (2023) (0)
- Transverse Myelitis (2018) (0)
- It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. (2021) (0)
- Melatonin and multiple sclerosis. (2021) (0)
- Influence of migration on the prognosis of neuromyelitis optica spectrum disorder in non-Caucasian patients (2019) (0)
- The Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease: A State-of-the-Art Review (2022) (0)
- Quality of Life in Patients With Neuromyelitis Optica (2018) (0)
- Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy. (2018) (0)
- A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder (2023) (0)
- NMOSDCopilot: Feasibility of Smartphone-Based Digital Biomarkers for the Self-Assessment of Vision, Motor and Cognitive Functions in Neuromyelitis Optica Spectrum Disorder (S50.002) (2023) (0)
- “Spinal” Movement Disorders in NMO Patients: An Under-Recognized Phenomenon (S46.001) (2015) (0)
- Microcystic Macular Edema in Neuromyelitis Optica Is Associated with Visual Disability and Retinal Axonal and Neuronal Loss (IN4-1.009) (2013) (0)
- requirements by permitting unilateral optic neuritis or asymptomatic brain MRI lesions (0)
- Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002) (2023) (0)
- Adoptive Transfer of T-cells Reactive to Aquaporin-4 Creates Neuromyelitis Optica Mouse Model (P4.006) (2014) (0)
- It’s Not All Transverse Myelitis: The Differential Diagnosis of Spinal Cord Myelopathy (S13.008) (2018) (0)
- Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (S5.003) (2023) (0)
- Upregulated complement receptors correlate with Fc gamma receptor 3A-positive natural killer and natural killer-T cells in neuromyelitis optica spectrum disorder (2022) (0)
- Treatment of Acute Relapses in Transverse Myelitis: Steroids Alone Versus Steroids Plus Plasma Exchange (P3.219) (2016) (0)
- Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort (2022) (0)
- Rates of True Positives and False Positives in Paraneoplastic Antibody Testing in Neurological Diseases (P6.116) (2016) (0)
- Trial of C1-Esterase Inhibitor in Acute Relapses of Neuromyelitis Optica (P4.004) (2014) (0)
- Is Corticospinal Tract Degeneration Caused by Sjögren Syndrome? (2018) (0)
- Passive Transfer of NMO-IgG Does Not Exacerbate EAE in AQP4 null mice (P2.196) (2015) (0)
- A Phase II, Randomized, Double-blind, Sham-Controlled Clinical Trial of Transcutaneous Electrical Nerve Stimulation (TENS) Therapy for the Treatment of Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders (P13-5.005) (2023) (0)
- Hormonal Exposures Relate to Clinical Phenotype in Women with Neuromyelitis Optica (S12.005) (2016) (0)
- Long-Term Eculizumab in AQP4+ NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension (2022) (0)
- Clinical Criteria To Distinguish Vascular Myelopathy from Transverse Myelitis (P02.117) (2013) (0)
- Differential Diagnosis of Transverse Myelitis (P2.274) (2014) (0)
- Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial (2022) (0)
- Brainstem Manifestations in Neuromyelitis Optica (P02.144) (2013) (0)
- Cognitive function in Egyptian Neuromyelitis Optica Spectrum Disorder (2020) (0)
- Clinical Predictors of Death in Neuromyelitis Optica Spectrum Disorders (P2.329) (2017) (0)
- Guiding cell-based therapy for neurological diseases with noninvasive cellular imaging (2009) (0)
- 2189 Scrambler therapy: Potential new treatment for central neuropathic pain? (2018) (0)
- Upregulated Complement Receptors Correlate With Fc Gamma Receptor 3A-Positive Natural Killer Cells (NK) and Natural Killer-T Cells (NKT) in Neuromyelitis Optica Spectrum Disorder (2022) (0)
- Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (2021) (0)
- Practical Experience with Animal Models for Translational Research in MS and NMO (P5.309) (2016) (0)
- Contributors to Long-Term Disability in Patients with Neuromyelitis Optica Spectrum Disorder (2018) (0)
- Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299) (2020) (0)
- Earlier Treatment of Acute Relapses in Neuromyelitis Optica Spectrum Disorder Leads to Better Outcomes (P6.385) (2017) (0)
- Laquinimod Prevents NMOIg-Induced Disease Exacerbation in a Model of Neuromyelitis Optica. (P4.003) (2014) (0)
- Benefit of Eculizumab for a Broad Range of Patients with Aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study (1299) (2020) (0)
- Distinguishing slow flow spinal arteriovenous fistulas from idiopathic transverse myelitis: a retrospective study of 94 patients (P4.069) (2015) (0)
- Characterization of Neurosarcoid Myelitis and Assessment of Treatment Response: A Multicenter Retrospective Study (2022) (0)
- Efficacy and safety of eculizumab in aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder: A phase 3, randomized, double-blind, placebo-controlled, multicenter trial (PREVENT) (2019) (0)
- Processing Speed and Informant Reports of Executive Functioning in Neuromyelitis Optica (P5.254) (2015) (0)
- Impact Of Eculizumab On Quality Of Life In AQP4+NMOSD: Findings From The PREVENT Study (2020) (0)
- Analyses Of Neural Autoantibodies By a Clinical Laboratory For The Evaluation Of Paraneoplastic And Non-Paraneoplastic Neuronal Disorders (P6.001) (2014) (0)
- Reply: (2019) (0)
- Impact of Eculizumab on Disability Worsening and Quality of Life in Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder: Results from the Phase 3 PREVENT Study (1658) (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Levy?
Michael Levy is affiliated with the following schools:
